An inexpensive home meter to monitor CKD and heart failure directly in a drop of blood

授权患者就其健康做出及时和适当的决定，可以从根本上改变医疗保健的消费。例如，最近在连续血糖监测方面的进展使胰岛素依赖型糖尿病患者能够滴定胰岛素剂量，从而以持续的方式实现更严格的血糖控制。在慢性肾病（CKD）、心力衰竭（HF），甚至炎症或免疫反应介导的疾病（如冠状动脉疾病（CVD）和乳糜泻（CD））中，也有机会推动类似的基于诊断的中断。蒙特利尔大学（University of Montreal）的vallsame - bsamisle实验室最近报告了一系列基于dna的电化学检测方法，并申请了专利，这些方法可以在家里从一滴全血中进行实验室质量测量，从而使患者能够实时滴定其治疗方法。该项目将提供科学和工程证据，以确定开发基于电化学dna的原型传感器的技术可行性，并将开发该原型，用于检测国内CKD和HF监测的3个关键标志物。

Empowering patients to make timely and appropriate decisions regarding their health can fundamentally change the consumption of healthcare. For example, recent advances in continuous glucose monitoring have enabled insulin-dependent diabetes patients to titrate their insulin dosing and hence achieve tighter glycemic control in a sustained manner. There is an opportunity to drive similar diagnostic-based disruption in Chronic Kidney Disease (CKD), Heart Failure (HF) and even inflammation or immune response mediated diseases such as Coronary Vascular Disease (CVD) and celiac disease (CD). The Vallée-Bélisle lab at the University of Montreal recently reported and patented a family of electrochemical DNA-based assays that can deliver lab quality measurements at home from one drop of whole blood, thereby enabling the patient to titrate its therapy in real-time. The proposed project will provide scientific and engineering evidence establishing the technical feasibility to develop a prototype electrochemical DNA-based sensor and will develop this prototype for the detection of 3 key markers for monitoring CKD and HF at home.